Table 1 Differences in study parameters between patients with GEP-NET and control group
From: Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?
Parameters | GEP-NET patients n. 109 | Control group n. 109 | *p-value |
|---|---|---|---|
Demographic characteristics | |||
Gender (Males) | 53 (48.6%) | 53 (48.6%) | χ2 = 0.02, p = 0.892 |
Age (years) | 57.1 ± 16.0 | 56.2 ± 12.9 | 0.370 |
Clinical characteristics | |||
Smoking (No) | 72 (66.1%) | 42 (38.5%) | χ2 = 16.54, p < 0.001 |
Physical activity (No) | 60 (55.0%) | 55 (50.5%) | χ2 = 0.29, p = 0.587 |
Anthropometric measurement | |||
BMI (kg/m2) | 27.6 ± 5.3 | 28.2 ± 4.1 | 0.364 |
Normal weight (n, %) | 38 (34.9%) | 27 (24.8%) | χ2 = 2.19, p = 0.099 |
Overweight (n, %) | 36 (33.0%) | 53 (48.6%) | χ2 = 4.86, p = 0.028 |
Grade I obesity (n, %) | 29 (26.6%) | 22 (20.2%) | χ2 = 0.92, p = 0.337 |
Grade II obesity (n, %) | 5 (4.6%) | 6 (5.5%) | χ2 = 0.01, p = 1.000 |
Grade III obesity (n, %) | 1 (0.9%) | 1 (0.9%) | χ2 = 0.51, p = 0.478 |
WC Males (cm) | 97.4 ± 13.5 | 92.9 ± 10.3 | 0.049 |
WC Females (cm) | 90.5 ± 15.2 | 84.1 ± 9.8 | 0.008 |
Blood pressure | |||
SBP (mmHg) | 125.2 ± 12.0 | 120.5 ± 12.4 | 0.007 |
DBP (mmHg) | 76.7 ± 7.7 | 75.5 ± 7.9 | 0.209 |
Metabolic profile | |||
Glycemia levels (mg/dL) | 108.1 ± 15.5 | 92.4 ± 14.6 | < 0.001 |
Total cholesterol (mg/dL) | 190.9 ± 41.8 | 159.0 ± 30.9 | < 0.001 |
Triglycerides (mg/dL) | 127.1 ± 51.6 | 109.7 ± 28.8 | 0.003 |
LDL cholesterol (mg/dL) | 118.7 ± 40.0 | 86.7 ± 31.2 | < 0.001 |
HDL cholesterol (mg/dL) | 46.8 ± 15.3 | 50.3 ± 8.1 | 0.034 |
MetS | |||
Number parameter | 2.1 ± 1.5 | 1.0 ± 1.1 | < 0.001 |
Mets presence | 40 (36.7%) | 15 (13.8%) | χ2 = 14.00, p = 0.001 |